Ovarian carcinoma cells with low levels of β-F1-ATPase are sensitive to combined platinum and 2-deoxy-D-glucose treatment

Molecular Cancer Therapeutics

Volumn 8, Issue 7, 2009, Pages 1916-1923

  Hernlund, Emma ^a   Hjerpe, Elisabet ^a,b   Åvall Lundqvist, Elisabeth ^a,b   Shoshan, Maria ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARBOPLATIN; CISPLATIN; DEOXYGLUCOSE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE;

ARTICLE; ASCITES; CANCER RESISTANCE; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG POTENTIATION; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; IC 50; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARBOPLATIN; CELL PROLIFERATION; CISPLATIN; DEOXYGLUCOSE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; LACTIC ACID; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 67651180715     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0179     Document Type: Article

References (28)

1. Landen CN, Jr., Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008;26:995-1005.
2. Fracasso PM. Overcoming drug resistance in ovarian carcinoma. Curr Oncol Rep 2001;3:19-26.
3. Shaw RJ. Glucose metabolism and cancer. Curr Opin Cell Biol 2006;18: 598-608.
4. Harper ME, Antoniou A, Villalobos-Menuey E, et al. Characterization of a novel metabolic strategy used by drug-resistant tumor cells. FASEB J 2002;16:1550-7.
5. Cuezva JM, Krajewska M, de Heredia ML, et al. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 2002;62: 6674-81.
6. Chen Z, Lu W, Garcia-Prieto C, Huang P. The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 2007;39:267-74.
7. Isidoro A, Martinez M, Fernandez PL, et al. Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem J 2004;378:17-20.
8. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006;25:4633-46.
9. Datema R, Lezica RP, Robbins PW, Schwarz RT. Deoxyglucose inhibition of protein glycosylation: effects of nucleotide deoxysugars on the formation of glucosylated lipid intermediates. Arch Biochem Biophys 1981; 206:65-71.
10. Coleman MC, Asbury CR, Daniels D, et al. 2-Deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. Free Radic Biol Med 2008;44:322-31.
11. Singh D, Banerji AK, Dwarakanath BS, et al. Optimizing cancer radiotherapy with 2-deoxy-D-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 2005;181:507-14.
12. Hernlund E, Ihrlund LS, Khan O, et al. Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int J Cancer 2008;123:476-83.
13. Ihrlund LS, Hernlund E, Khan O, Shoshan MC. 3-bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Mol Oncol 2008;2:94-101.
14. Isidoro A, Casado E, Redondo A, et al. Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 2005;26:2095-104.
15. Hagg M, Biven K, Ueno T, et al. A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs 2002;20:253-9.
16. Cuezva JM, Chen G, Alonso AM, et al. The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. Carcinogenesis 2004;25:1157-63.
17. Mandic A, Viktorsson K, Molin M, et al. Cisplatin induces the proapoptotic conformation of Bak in a δMEKK1-dependent manner. Mol Cell Biol 2001;21:3684-91.
18. Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 2003;278:9100-6.
19. Mandic A, Viktorsson K, Strandberg L, et al. Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis. Mol Cell Biol 2002;22:3003-13.
20. Berndtsson M, Hagg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer 2007;120:175-80.
21. Kramer G, Erdal H, Mertens HJ, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004;64:1751-6.
22. Lin X, Zhang F, Bradbury CM, et al. 2-Deoxy-D-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res 2003;63:3413-7.
23. Kurtoglu M, Gao N, Shang J, et al. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Ther 2007;6: 3049-58.
24. Goodisman J, Hagrman D, Tacka KA, Souid AK. Analysis of cytotoxicities of platinum compounds. Cancer Chemother Pharmacol 2006;57: 257-67.
25. Oguri S, Sakakibara T, Mase H, et al. Clinical pharmacokinetics of carboplatin. J Clin Pharmacol 1988;28:208-15.
26. Yang Z, Schumaker LM, Egorin MJ, Zuhowski EG, Guo Z, Cullen KJ. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin Cancer Res 2006;12:5817-25.
27. Shoshan-Barmatz V, Israelson A, Brdiczka D, Sheu SS. The voltage-dependent anion channel (VDAC): function in intracellular signalling, cell life and cell death. Curr Pharm Des 2006;12:2249-70.
28. Liu H, Hu YP, Savaraj N, Priebe W, Lampidis TJ. Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry 2001;40:5542-7.